Immunogenicity
. | . | Maximum titer, NHS units (weeks after injection) . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Cohort . | Patient . | HAFA . | HASA . | Anti-murine . | Follow-up, wk . | ||
| A | 1 | N | 7 (28) | N | 55 | ||
| A | 2 | N | N | N | 12 | ||
| A | 3 | N | N | N | 42 | ||
| B | 4 | 6 (13) | N | 5 (13) | 25 | ||
| B | 5 | N | N | N | 17 | ||
| B | 6 | 683 (3) | 1527 (7) | 42 (3) | 39 | ||
| B | 8 | N | N | N | 14 | ||
| C | 9 | 231 (4) | 642 (4) | 22 (4) | 22 | ||
| C | 10 | 208 (4) | 65 (6) | 102 (4) | 29 | ||
| C | 11 | 4 (4) | N | N | 15 | ||
| C | 12 | N | 11 (26) | N | 36 | ||
| D | 13 | 3 (2) | 4 (4) | N | 12 | ||
| D | 14 | N | N | N | 7 | ||
| D | 15 | N | N | N | 7 | ||
. | . | Maximum titer, NHS units (weeks after injection) . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Cohort . | Patient . | HAFA . | HASA . | Anti-murine . | Follow-up, wk . | ||
| A | 1 | N | 7 (28) | N | 55 | ||
| A | 2 | N | N | N | 12 | ||
| A | 3 | N | N | N | 42 | ||
| B | 4 | 6 (13) | N | 5 (13) | 25 | ||
| B | 5 | N | N | N | 17 | ||
| B | 6 | 683 (3) | 1527 (7) | 42 (3) | 39 | ||
| B | 8 | N | N | N | 14 | ||
| C | 9 | 231 (4) | 642 (4) | 22 (4) | 22 | ||
| C | 10 | 208 (4) | 65 (6) | 102 (4) | 29 | ||
| C | 11 | 4 (4) | N | N | 15 | ||
| C | 12 | N | 11 (26) | N | 36 | ||
| D | 13 | 3 (2) | 4 (4) | N | 12 | ||
| D | 14 | N | N | N | 7 | ||
| D | 15 | N | N | N | 7 | ||
NHS indicates normal human serum pool; positive response defined in “Patients, materials and methods.” N indicates negative.